The Best of Lung Cancer 2022 Hybrid Conference
This full-day hybrid event takes the most significant lung cancer data from the ASCO 2022 and ESMO 2022 conferences, putting the data into context for oncology professionals. Speakers will review the latest research with in-depth analysis and discussion to improve the current standard of lung cancer care.
- Describe emerging strategies for immunotherapy and targeted therapy in non-small cell lung cancer, in both early stage and metastatic disease
- Describe the emergence of novel issues in lung cancer, including vaping, robotic surgery, artificial intelligence, liquid biopsies and medical assistance in dying
- Describe standard of care variations and latest advances in radiotherapy and systemic therapy in small cell lung cancer
Friday, September 16, 2022
Join Us Live In Person
at the
BMO Institute for Learning, Toronto
Registration for Healthcare professionals can be completed below. Industry representatives (both sponsor and non-sponsor) must contact Kelly Allan at kelly@oncologyeducation.ca for registration and sponsorship opportunities.
Buy Tickets
In Person & Virtual Options Below:
Scientific Agenda
Times listed are EST
7:00am – 8:00am
Registration and Breakfast Buffet
8:00am – 8:15am
Welcome Address by Chairs – Dr. Paul Wheatley-Price & Dr. Stephanie Snow
8:15am – 9:00am
BMS Breakfast Symposium: New Perspective in I-O to Early-Stage Lung Cancer
9:00am – 9:25am
From beginning to end: E-Cigarettes and Vaping: Profit and Toxicity – Prof. David Hammond
9:25am – 9:50am
From beginning to end: Medical assistance in dying (MAID) in lung cancer patients – Dr. Sara Moore
9:50am – 10:10am
Networking Break & Sponsor Exhibits
10:10am – 10:35am
Targeted Therapy, Where Are we with KRAS? – Dr. Adrian Sacher
10:35am – 11:00am
Antibody-Drug Conjugates – Dr. Quincy Chu
11:00am – 11:25am
New Immunotherapy Combinations: Making Cold Tumors Hot – Dr. Rosalyn Juergens
11:25am – 11:40am
Panel for Novel Therapies – Dr. Adrian Sacher, Dr. Quincy Chu & Dr. Rosalyn Juergens
11:40am – 12:10pm
Lunch Break
12:10pm – 12:55pm
AstraZeneca Lunch Symposium: Next Steps for Targeted Therapy in Resectable NSCLC – TBA
12:55pm – 1:20pm
Radiotheraphy in Limited Stage Small Cell: Should We Set a Standard? – Dr. Benjamin Lok
1:20pm – 1:45pm
Updates in Systemic Therapy for Extensive Stage Small Cell Lung Cancer – Dr. Aliyah Pabani
1:45pm – 2:05pm
Networking Break & Sponsor Exhibits
2:05pm – 2:40pm
New technologies: Robotic Surgery – Dr. Waël Hanna
2:40pm – 3:05pm
Liquid Biopsies – ‘Emerging Technologies’ Could be the Current State of Liquid Biopsies? – TBA
3:05pm – 3:20pm
Closing Remarks by Chairs – Dr. Paul Wheatley-Price & Dr. Stephanie Snow
About the Faculty
Dr. Paul Wheatley-Price
Conference Chair
Dr. Paul Wheatley-Price is Associate Professor in the Department of Medicine at the University of Ottawa, and a medical oncologist at The Ottawa Hospital Cancer Centre, specializing in the treatment of thoracic malignancies and carcinoma of unknown primary.
Dr. Wheatley-Price is a Past President and ongoing Board member for Lung Cancer Canada. Dr. Wheatley-Price attended medical school in the UK, at the University of St. Andrews (1991-1994) and the University of Manchester (1994 – 1997).
He received specialist medical oncology training in Wellington, New Zealand, in London at the Royal Free Hospital, Guy’s and St. Thomas’ Hospitals and St. George’s Hospital, and as a Fellow in Lung Cancer Research at Princess Margaret Cancer Centre in Toronto.
He has been in Ottawa since 2009.
Dr. Stephanie Snow
Conference Chair
Dr. Stephanie Snow has been a staff Medical Oncologist at the QEII hospital in Halifax, Nova Scotia since 2010 and is currently an Associate Professor at in the Faculty of Medicine at Dalhousie. After pursuing undergraduate training at McGill, she completed her MD, Internal Medicine and Medical Oncology training at Dalhousie. She treats head and neck, thoracic and GI malignancies. She has a strong interest in Medical Education and is a member of the Royal College Medical Oncology Examination Board. She also has a keen interest in patient advocacy, serving as the current President of Lung Cancer Canada, and sitting on the medical advisory committees of several other patient advocacy groups in colorectal and gastric cancer.
Sponsorship
PLATINUM
GOLD
SILVER
BRONZE
